bioRxiv Science⌕ Search

Biology subjects

Gagni, P.

Publications and source records attributed to Gagni, P..

4 recordsLinked to original sources

Enhanced Workflow for Urinary Extracellular Vesicle Isolation Using Membrane-Sensing Peptides

Urinary extracellular vesicles (uEVs) represent a promising source of non-invasive biomarkers; however, their clinical translation is still limited by suboptimal isolation strategies, which often suffer from poor scalability, co-isolation of abundant urinary proteins, and bias toward specific EV subpopulations. Here, we employ a membrane-sensing peptide (MSP)-based affinity approach for uEVs isolation, that exploits the highly lipid membranes curvature of EV as universal target, enabling pan-specific capture independent of surface marker expression. MSP-functionalized beads were applied to minimally processed urine samples and benchmarked against differential ultracentrifugation (dUC) and size-exclusion chromatography (SEC). Comprehensive characterization by nanoparticle tracking analysis, transmission electron microscopy, high-sensitivity flow cytometry, single-molecule array (SiMoA), and fluorescence nanoparticle tracking analysis, demonstrated that MSP-based isolation preserves vesicle integrity and maintains the native distribution of canonical tetraspanins (CD9, CD63, CD81), without evidence of subpopulation bias. Notably, MSP-based isolation significantly reduced co-isolated contaminants, such as uromodulin, resulting in improved sample purity. By combining high recovery, improved purity, and operational simplicity, MSP workflow offers practical advantages, including reduced processing time, scalability, and compatibility with standard laboratory equipment, without the need for extensive pre-processing. These properties characterize MSP-based affinity capture as a robust and versatile alternative to conventional uEVs isolation approaches, with strong potential for translational and clinical applications.

biochemistry↗

Membrane Sensing Peptides -Enhanced SiMoA Platform for the Detection of HER2 on Extracellular Vesicles in Metastatic Breast Cancer Patients

Extracellular vesicles (EVs) offer a promising avenue for non-invasive, real-time monitoring of metastatic breast cancer (mBC), but clinical application as a liquid biopsy is hindered by their heterogeneity and low abundance. Here we present a Single Molecule Array (SiMoA) platform enhanced by membrane sensing peptides (MSP) for the highly sensitive detection of HER2 on EV membranes (EVs-HER2) and general EVs population (CD9+) directly from plasma samples of mBC patients. The MSP-based SiMoA assay demonstrated superior sensitivity and specificity compared to conventional antibody-based assays, allowing the detection of lower amounts of EVs and discriminating EVs derived from breast cancer patient-derived organoids (BC-PDO) from healthy control-derived organoids (HC-PDO). Concerning the analysis of EVs in plasma samples (n=49 mBC patients, n=30 healthy controls), we observed significantly lower CD9+ EVs levels in mBC patients relative to healthy controls, a trend consistently confirmed across assays. Notably, EVs-HER2 levels were significantly enriched in HER2-positive patients and correlated with clinical HER2 status assessed by immunohistochemistry. Besides, lower CD9+ EVs levels were associated with poorer clinical outcomes, highlighting the potential prognostic utility of EV quantification. Our findings underscore the potential of MSP-enhanced SiMoA platforms for accurate, minimally invasive monitoring of EVs-HER2 in mBC and for monitoring CD9+ EVs levels to assess disease progression.

biochemistry↗

MICROGLIAL EXTRACELLULAR VESICLES MEDIATE C1Q DEPOSITION AT THE PRE-SYNAPSE AND PROMOTE SYNAPTIC PRUNING

C1q is released by microglia, localizes on weak synapses and acts as a tag for microglial synaptic pruning. However, how C1q tags synapses during the pruning period remains to be fully elucidated. Here, we report that C1q is delivered by microglia to pre-synaptic sites that externalize phosphatidylserine through extracellular vesicles. Using approaches to increase or reduce vesicles production in microglia, by C9orf72 knock out or pharmacological inhibition respectively, we provided mechanistic evidence linking extracellular vesicle release to pre-synaptic remodelling in neuron-microglia cultures. In C9orf72 knockout mice, we confirmed larger production of microglial extracellular vesicles, and showed augmented C1q presynaptic deposition associated with enhanced engulfment by microglia in the early postnatal hippocampus. Finally, we provide evidence that microglia physiologically release more vesicles during the period of postnatal circuit refinement. These findings implicate abnormal release of microglial extracellular vesicles in both neurodevelopmental and age-related disorders characterized by dysregulated microglia-mediated synaptic pruning.

neuroscience↗

Addressing heterogeneity in direct analysis of Extracellular Vesicles and analogues using Membrane-Sensing Peptides as Pan-Affinity Probes

Extracellular vesicles (EVs), crucial mediators of cell-to-cell communication, hold immense potential for diagnostic applications due to their ability to enrich protein biomarkers in body fluids. However, challenges in isolating EVs from complex biological specimens hinder their widespread use. In this frame, integrated isolation-and-analysis workflows are the go-to strategy, most of which see the prevalence of immunoaffinity methods. Yet, the high heterogeneity of EVs poses challenges, as proposed ubiquitous markers are less homogenously prevalent than believed, raising concerns about the reliability of downstream biomarker discovery programs. This issue extends to the burgeoning field of engineered EV-mimetics and bio-nanoparticles, where conventional immune-affinity methods may lack applicability. Addressing these challenges, we introduce the use Membrane Sensing Peptides (MSP) as "universal" affinity ligands for both EVs and EV-analogues. Employing a streamlined process integrating on-bead capture and vesicle phenotyping through Single Molecule Array (SiMoA) technology, we showcase the application of MSP ligands in the integrated analysis of circulating EVs in blood derivatives, eliminating the need for prior EV isolation. Demonstrating the possible clinical translation of MSP technology, we directly detect an EV-associated epitope signature in serum and plasma samples, demonstrating its potential for distinguishing patients with myocardial infarction versus stable angina. At last, notably, MSP exhibits a unique capability to enable the analysis of tetraspanin-lacking Red Blood Cell derived EVs (RBC-EVs). Overall, unlike traditional antibody-based methods, MSP probes work agnostically, overcoming limitations associated with surface protein abundance or scarcity. This highlights the potential of MSP in advancing EV analysis for clinical diagnostics and beyond. Of note, this represents also the first-ever peptide-based application in SiMoA technology.

biochemistry↗